medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2016, Number 1

<< Back Next >>

Residente 2016; 11 (1)

Enfermedad aterosclerótica coronaria en artritis reumatoide

Olvera-Palafox CN, Flores-Chávez A, Romero-Moreno JR, Cardona-Müller D, Trujillo-Trujillo X, González-López L

Language: Spanish
References: 50
Page: 19-27
PDF size: 248.44 Kb.


ABSTRACT

In the mechanism of subclinical atherosclerosis in patients with RA, it described the influence of the presence of traditional risk factors like autoimmune inflammatory process and mechanism. Autoantibodies, autoantigens, proinflammatory cytokines and infectious agents play a important role in this process. In RA, there has been an increased incidence of atherosclerosis accelerated; in patients with RA, vascular function is impaired and the process of atherosclerosis seems It is accelerated due to various factors, such as increased arterial stiffness, elasticity reductions blood, deterioration in endothelial response, increased thickness of the intima-media and content coronary calcium, which are modified due to the presence of severe inflammation present in these subjects and, in turn, they represent an increased risk of cardiovascular morbidity and mortality


REFERENCES

  1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001; 358 (9285): 903-911.

  2. Rodríguez MA. Artritis reumatoide. En: Alarcón SD, Molina LJ (editores). Tratado hispanoamericano de reumatología. Bogotá: Editorial Nomos; 2006. pp. 435-500.

  3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094-108.

  4. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res ClinRheumatol. 2002; 16 (5): 707-722.

  5. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J et al. Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

  6. Scarno A, Perrotta FM, Cardini F et al. Beyond the joint: subclinical atherosclerosis in rheumatoid arthritis. World J Orthop. 2014; 5 (3): 328-335.

  7. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59: 1690-1697.

  8. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008; 121: S21-S31.

  9. Meune C, Touzé E, Trinquart L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Reumatology. 2009; 48 (10): 1309-1313.

  10. Choi HK, Rho Y-H, Zhu Y et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013; 72 (7): 1182-1187.

  11. Choy E, Sattar N. Interpreting lipids levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009; 68: 360-469.

  12. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107: 1303-1307.

  13. Goodson NJ, Silman AJ, Pattison DJ et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford). 2004; 43: 731-736.

  14. Del Rincón I, Polak JF, O’Leary DH et al. Systemic inflammation and cardiovascular risk factor predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015; 74 (6): 1118-1123.

  15. Deo SS, Chogle AR, Mistry KJ et al. Increased prevalence of subclinical atherosclerosis in rheumatoid arthritis patients of Indian descent. Exp Clin Cardiol. 2012; 17 (1): 20-25.

  16. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014; 53: 2143-2154.

  17. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011; 63 (11): 3216-3225.

  18. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other inflammatory arthritis. Ann Rheum Dis. 2010; 69 (2): 325-331.

  19. Koivuniemi R, Paimela L, Suomalainen R et al. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatoil. 2013; 42 (2): 131-135.

  20. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases –mechanisms and clinical findings. Clin Rev Allergy Immunol. 2009; 37 (1): 20-28.

  21. Bartoloni E, Alunno A, Bistoni O et al. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev. 2010; 9 (10): 701-707.

  22. Ku IA, Imboden JB, Hsue PY et al. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J. 2009; 73 (6): 977-985.

  23. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis. 2002; 46: 862-873.

  24. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767-1772.

  25. Ridker P, Hennekens C, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998; 351: 88-92.

  26. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-2168.

  27. Molrnaar E, Voskuyl A, Familian A, Van Mierlo G, Dijkmans B, Hack C. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001; 44: 997-1002.

  28. Meek RL, Urieli-Shoval S, Benditt E. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA. 1994; 91: 3186-90.

  29. Lazarevic MB, Vitic J, Mladenovic V et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992; 22: 172-178.

  30. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol. 2000; 19: 324-325.

  31. Hernanz A, Plaza A, Martín-Mola E et al. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999; 32: 65-70.

  32. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100: 2124-2126.

  33. Turesson C, McClelland RL, Christianson TJ. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 70-75.

  34. Jacobsson LT, Turesson C, Hanson RL et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 2001; 44: 1170-1176.

  35. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233-241.

  36. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051.

  37. Pasceri V, Willerson J, Yeh. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-2168.

  38. Meek R, Urieli-Shoval S, Benditt E. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. ProcNatlAcadSci USA. 1994; 91: 3186-90.

  39. James M, van Reyk D, Tye K et al. Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipids. 1998; 33: 1115-1121.

  40. Winyard P, Tatzber F, Esterbauer H et al. Presence of foam cells containing oxidized low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis. 1993; 52: 677-680.

  41. Kume N, Murase T, Moriwaki H et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998; 83: 332-337.

  42. Nagase M, Abe J, Takahashi K et al. Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-) gene. J Biol Chem. 1998; 272: 33702-33707.

  43. Memon R, Staprans Y, Noor M et al. Infection and inflammation induce LDL oxidation in vivo. Arterioescler Thromb Vasc Biol. 2000; 20: 1536-1542.

  44. Canalizo-Miranda E, Favela-Pérez EA, Salas-Anaya JA et al. Guía de práctica clínica: diagnóstico y tratamiento de las dislipidemias. Rev Med Inst Mex Seg Soc. 2013; 51 (6): 700-709.

  45. Ministry of Health. Clinical practice guidelines. Lipids. Singapore: Ministry of Health; 2006.

  46. Scott M, Grundy MD, Becker D, Clark LT et al. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood colesterol in adults. Adult Treatment Panel III. NIH. 2002; 2: V1-V28.

  47. Castro-González MI. Ácidos grasos omega 3: beneficios y fuentes. Redalyc. 2002; 27 (3): 128-136.

  48. Escudero-Alvarez E, González-Sanchez P. La fibra dietética. NutrHosp. 2006; 21 (2): 61-72.

  49. Fischer LM, Schlienger RG, Matter CM. Discontinuation of non steroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med. 2004; 164: 2472-2476.

  50. Fonarow GC. Aggressive treatment of atherosclerosis: the time is now. Cleve Clin J Med. 2003; 70 (5): 431-434, 437-438, 440.




2020     |     www.medigraphic.com